Cronograma de promoção Exact Sciences Corporation
Sobre a empresa
Exact Sciences Corporation предлагает продукты для скрининга и диагностики рака в США и за рубежом. Компания предлагает Cologuard, неинвазивный ДНК-скрининг-тест на основе стула для выявления колоректального рака и предраковых состояний. Он также предоставляет Oncotype DX, тесты экспрессии генов для рака груди, простаты и толстой кишки; и Oncotype DX AR-V7 Nucleus Detect Test, жидкий тест для рака простаты на поздней стадии. Продукция компании сосредоточена на исследованиях и разработках для улучшения рабочих характеристик Cologuard, а также на тестах крови или других жидкостей.
Mais detalhesP/S | 14.22 |
---|---|
P/BV | 5.45 |
EV/EBITDA | -60.76 |
EBITDA | -0.2177 |
Цена ао | 68.12 |
Сайт | http://www.exactsciences.com |
Число акций ао | 0.18014 млрд |
Выручка | 0.8763 |
Див.доход ао | 0 |
ISIN | US30063P1057 |
Валюта | usd |
IPO date | 2001-02-01 |
Sector | Health Care |
Industry | Biotechnology |
Валюта отчета | usd |
Alteração de preço por dia: | +2.34% (69.34) |
---|---|
Alteração de preço por semana: | +3.8% (68.36) |
Alteração de preço por mês: | +10.67% (64.12) |
Alteração de preço em 3 meses: | +50.82% (47.05) |
Mudança de preço em seis meses: | +8.58% (65.35) |
Mudança de preço por ano: | +9.86% (64.59) |
Mudança de preço em 3 anos: | -9.17% (78.12) |
Mudança de preço em 5 anos: | -25.52% (95.28) |
Mudança de preço em 10 anos: | +182.48% (25.12) |
Mudança de preço desde o início do ano: | +7.03% (66.3) |
|
Subestimação
|
Eficiência
|
|||||||||||||||||||||||||||||||||||||
Dividendos
|
Obrigação
|
Impulso de crescimento
|
Data da transação | Data de divulgação | Insider | Tipo | Preço | Volume | Quantidade | Compartilhe até, % | Compartilhe depois, % | Documento |
---|---|---|---|---|---|---|---|---|---|
01.05.2024 | 02.05.2024 | Conroy Kevin T President and CEO |
Oferta | 60.15 | 69 473 | 1155 | 0 | 0 | link |
01.05.2024 | 02.05.2024 | ORVILLE JACOB A General Manager, Screening |
Oferta | 60.15 | 6 135 | 102 | 0 | 0 | link |
01.05.2024 | 02.05.2024 | Condella Sarah EVP, Human Resources |
Oferta | 60.15 | 6 135 | 102 | 0 | 0 | link |
01.05.2024 | 02.05.2024 | Baranick Brian EVP, GM., Precision Oncology |
Oferta | 60.15 | 6 617 | 110 | 0 | 0 | link |
01.05.2024 | 02.05.2024 | Elliott Jeffrey Thomas Chief Financial Officer |
Oferta | 60.15 | 8 180 | 136 | 0 | 0 | link |
01.05.2024 | 02.05.2024 | Herriott James SVP, General Counsel & Sec |
Oferta | 60.15 | 1 805 | 30 | 0 | 0 | link |
01.05.2024 | 02.05.2024 | Cunningham Everett Chief Commercial Officer |
Oferta | 60.15 | 8 180 | 136 | 0 | 0 | link |
01.05.2024 | 02.05.2024 | COWARD D SCOTT Director |
Oferta | 60.15 | 4 030 | 67 | 0 | 0 | link |
28.03.2024 | 01.04.2024 | Condella Sarah EVP, Human Resources |
Oferta | 70 | 140 000 | 2000 | 0 | 0 | link |
22.02.2024 | 23.02.2024 | COWARD D SCOTT Director |
Oferta | 59.78 | 39 634 | 663 | 0 | 0 | link |
22.02.2024 | 23.02.2024 | Cunningham Everett Chief Commercial Officer |
Oferta | 59.78 | 80 703 | 1350 | 0 | 0 | link |
22.02.2024 | 23.02.2024 | Elliott Jeffrey Thomas Chief Financial Officer |
Oferta | 59.78 | 80 763 | 1351 | 0 | 0 | link |
22.02.2024 | 23.02.2024 | Herriott James General Counsel |
Oferta | 59.78 | 17 396 | 291 | 0 | 0 | link |
22.02.2024 | 23.02.2024 | ORVILLE JACOB A General Manager, Screening |
Oferta | 59.78 | 60 557 | 1013 | 0 | 0 | link |
01.09.2023 | 06.09.2023 | Condella Sarah EVP, Human Resources |
Oferta | 84.36 | 379 620 | 4500 | 0 | 0 | link |
12.10.2022 | 13.10.2022 | Cunningham Everett Chief Commercial Officer |
Oferta | 31.37 | 529 275 | 16872 | 0 | -0.01 | link |
11.10.2022 | 13.10.2022 | Cunningham Everett Chief Commercial Officer |
Comprar | 30.42 | 1 064 880 | 35006 | 0 | 0.02 | link |
10.06.2021 | 11.06.2021 | Condella Sarah SVP, Human Resources |
Oferta | 120 | 654 000 | 5450 | 0 | 0 | link |
10.06.2021 | 11.06.2021 | Condella Sarah SVP, Human Resources |
Comprar | 5.03 | 9 809 | 1950 | 0 | 0 | link |
25.02.2021 | 01.03.2021 | COWARD D SCOTT Chief Administrative Officer |
Oferta | 132.96 | 902 532 | 6788 | 0 | -0.01 | link |
19.02.2021 | 22.02.2021 | ORVILLE JACOB A General Manager, New Ventures |
Oferta | 143.38 | 243 172 | 1696 | 0 | 0 | link |
18.02.2021 | 22.02.2021 | COWARD D SCOTT Chief Administrative Officer |
Oferta | 140.79 | 278 764 | 1980 | 0 | 0 | link |
18.02.2021 | 22.02.2021 | ORVILLE JACOB A General Manager, New Ventures |
Comprar | 142.32 | 519 326 | 3649 | 0 | 0 | link |
14.12.2020 | 14.12.2020 | Zanotti Katherine S Director |
Oferta | 132.06 | 2 641 200 | 20000 | 0 | -0.02 | link |
Instituições | Volume | Compartilhar, % |
---|---|---|
Vanguard Group Inc | 17559751 | 9.67 |
JP Morgan Chase & Company | 16690808 | 9.19 |
Blackrock Inc. | 11053013 | 6.09 |
Wellington Management Group, LLP | 10280814 | 5.66 |
Capital World Investors | 7468145 | 4.11 |
ARK Investment Management, LLC | 6032893 | 3.32 |
State Street Corporation | 5020742 | 2.77 |
Artisan Partners Limited Partnership | 4470278 | 2.46 |
Baillie Gifford and Company | 3767055 | 2.08 |
T. Rowe Price Investment Management, Inc. | 2951302 | 1.63 |
Supervisor | Cargo | Pagamento | Ano de nascimento |
---|---|---|---|
Mr. Kevin T. Conroy | Chairman of The Board & CEO | 1.54M | 1966 (58 anos) |
Ms. Megan Jones | Associate Manager of Investor Relations | N/A | |
Mr. Tim Caprez | Chief Compliance Counsel & VP | N/A | |
Dr. Jorge A. Garces Ph.D. | Chief Science Officer | N/A | 1972 (52 ano) |
Mr. James Herriott | Senior VP, General Counsel & Secretary | N/A | 1980 (44 ano) |
Ms. Sarah Condella | Executive Vice President of Human Resources | 742.76k | 1981 (43 ano) |
Mr. Nassar Nizami | Chief Information Officer | N/A | |
Mr. Jake Orville MBA | Executive VP & General Manager of Pipeline | 1974 (50 anos) | |
Mr. Brian Baranick | Executive VP & General Manager of Precision Oncology | 1978 (46 anos) | |
Mr. Aaron Bloomer | Chief Financial Officer | 1986 (38 anos) |
Site: http://www.exactsciences.com